Stock analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
NASDAQ:TTNP opened at $3.57 on Wednesday. The business has a fifty day simple moving average of $3.46 and a two-hundred day simple moving average of $4.58. Titan Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- What is a Secondary Public Offering? What Investors Need to Know
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Steel Stocks to Gain Strength as Tariffs Reshape the Market
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
